Erschienen in:
01.04.2016 | Original Article
Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management
verfasst von:
Marie Le Moigne, Mélanie Saint-Jean, Adam Jirka, Gaëlle Quéreux, Lucie Peuvrel, Anabelle Brocard, Aurélie Gaultier, Amir Khammari, Dominique Darmaun, Brigitte Dréno
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 4/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Whereas vismodegib is effective in the treatment of locally advanced/metastatic basal cell carcinoma, dysgeusia and weight loss are common side effects of such treatment. The main objective of this study was to monitor the nutritional status of vismodegib-treated patients. Secondary objective was to assess the incidence of dysgeusia and the benefit of early nutritional management.
Methods
This prospective study included all patients who started vismodegib between October 2011 and May 2013 at Nantes University Hospital. Prior to July 2012, patients treated with vismodegib had not received any specific nutritional management (Historical cohort). Body weight and presence of dysgeusia were recorded monthly. Patients treated after July 2012 (Nutrition cohort) were evaluated by a physician of the Nutrition Support Unit and received dietary counseling at vismodegib initiation. A standardized nutritional management protocol was initiated in case of significant weight loss.
Results
Forty-five patients (21 and 24 in the Nutrition and Historical cohort, respectively) were enrolled. In the Nutrition cohort, five patients (24 %) were undernourished at vismodegib initiation, and the 6-month cumulative incidence of dysgeusia was 71 %. Eight patients (38 %) and 13 patients (54 %) had a weight loss greater than 5 % in the Nutrition and Historical cohort, respectively (p = 0.3727).
Conclusion
The results of this pilot study suggest the benefit of early nutritional screening. The potential benefit of nutritional support in this setting warrants further investigation.